Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
Göteborg, Sweden. In Mol Neurodegener, Dec 2015
BACKGROUND: The discovery that heterozygous missense mutations in the gene encoding triggering receptor expressed on myeloid cells 2 (TREM2) are risk factors for Alzheimer's disease (AD), with only the apolipoprotein E (APOE) ε4 gene allele conferring a higher risk, has led to increased interest in immune biology in the brain.
Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease.
London, United Kingdom. In Curr Opin Neurobiol, Nov 2015
Furthermore, recent identification of a low frequency mutation in the gene encoding the triggering receptor expressed in myeloid cells 2 protein (TREM2) confers increased risk of AD in LOAD cohorts with an effect size similar to that for APOE, until recently the only identified genetic risk factor associated with LOAD [9,10(••)] (Figure 1).
Variant of TREM2 associated with the risk of Alzheimer's disease.
Reykjavík, Iceland. In N Engl J Med, 2013
RESULTS: A rare missense mutation (rs75932628-T) in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2), which was predicted to result in an R47H substitution, was found to confer a significant risk of Alzheimer's disease in Iceland (odds ratio, 2.92; 95% confidence interval [CI], 2.09 to 4.09; P=3.42×10(-10)).
TREM2 variants in Alzheimer's disease.
London, United Kingdom. In N Engl J Med, 2013
BACKGROUND: Homozygous loss-of-function mutations in TREM2, encoding the triggering receptor expressed on myeloid cells 2 protein, have previously been associated with an autosomal recessive form of early-onset dementia.